XML 51 R23.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES
12 Months Ended
Dec. 31, 2019
INCOME TAXES  
INCOME TAXES

NOTE 18:    INCOME TAXES

The Company has no income tax expense due to operating losses incurred for the years ended December 31, 2019 and 2018.

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2019 and 2018 are as follows:

 

 

 

 

 

 

 

 

 

    

For the Years Ended

 

 

December 31, 

 

    

2019

    

2018

Deferred Tax Assets:

 

 

 

 

 

 

Net Operating Loss Carry Forward

 

$

17,166,000

 

$

13,596,000

Stock-Based Compensation

 

 

6,538,000

 

 

5,741,000

License Agreements

 

 

177,000

 

 

206,000

Research and Development

 

 

733,000

 

 

406,000

Charitable Contributions

 

 

9,000

 

 

3,000

Operating Lease Liability

 

 

115,000

 

 

 —

 

 

 

24,738,000

 

 

19,952,000

Less: Valuation Allowance

 

 

(24,632,000)

 

 

(19,952,000)

Total Deferred Tax Assets

 

 

106,000

 

 

 —

 

 

 

 

 

 

 

Deferred Tax Liabilities

 

 

 

 

 

 

Fixed Assets

 

 

(106,000)

 

 

 —

 

 

 

 

 

 

 

Total Deferred Tax Liabilties

 

 

(106,000)

 

 

 —

 

 

 

 

 

 

 

Net Deferred Tax Assets/(Liabilities)

 

$

 —

 

$

 —

 

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2019 and 2018. The valuation allowance increased by $4.7 million as of December 31, 2019. The Company has research and development tax credit carryforwards of $730,000 available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.

The Company has approximately $73.8 million of federal and $47.4 million of state Net Operating Losses (“NOL”s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.9 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $31.9 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9  million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $25.5 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

The Company’s income tax returns for 2015 to 2018 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.

For the years ended December 31, 2019 and 2018, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

For the Years Ended December 31,

 

 

 

2019

 

2018

 

 

 

 

 

 

Percent of

 

 

 

 

Percent of

 

 

    

 

Amount

    

Pretax Income/(Loss)

    

 

Amount

    

Pretax Income/(Loss)

    

U.S. federal statutory rate

 

$

(4,500,000)

 

21.00

%  

$

(31,071,000)

 

21.00

%

State taxes, net of federal benefit

 

 

(600,000)

 

2.80

%  

 

(1,383,000)

 

0.93

%

Tax rate change

 

 

665,000

 

(3.10)

%  

 

 —

 

0.00

%

Permanent Differences

 

 

  

 

  

 

 

  

 

  

 

- Non-deductible write-off of acquired R&D expenses

 

 

 —

 

0.00

%  

 

24,369,000

 

(16.47)

%

- Change in fair value of derivative liabilities

 

 

(4,000)

 

0.02

%  

 

8,000

 

(0.01)

%

- Other permanent differences

 

 

32,000

 

(0.15)

%  

 

4,000

 

0.00

%

Change in valuation allowance

 

 

4,681,000

 

(21.85)

%  

 

8,073,000

 

(5.46)

%

Deferred true-up

 

 

(274,000)

 

1.28

%  

 

 —

 

0.00

%

Income tax provision/(benefit)

 

$

 —

 

0.00

%  

$

 —

 

0.00

%

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2019, and 2018, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2019 and 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.